Marc Semigran

MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.

The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA.

Broadview Ventures, Inc. (Broadview Ventures) is a venture capital firm founded in 2008. The firm is headquartered in Boston, Massachusetts.

Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA.

Social Capital Suvretta Holdings Corp. III is a blank check company, which was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Henderson, NV.

Renovacor, Inc. operates as a clinical stage gene therapy company. It researches and develops AAV-based gene therapies for BAG3 gene mutation-associated diseases. Its therapeutic focus is on cardiovascular diseases. The company was founded by Arthur Michael Feldman on June 7, 2013 and is headquartered in Cambridge, MA.